Impact of Obesity on the IL-6 Immune Marker and Th17 Immune Cells in C57BL/6 Mice Models with Imiquimod-Induced Psoriasis

Int J Mol Sci. 2023 Mar 15;24(6):5592. doi: 10.3390/ijms24065592.

Abstract

Obese psoriatic patients experience higher disease severity and exhibit poorer treatment responses and clinical outcomes. It has been proposed that proinflammatory cytokines produced by adipose tissue exacerbate psoriasis; however, the role of obesity in psoriasis remains unclear. This study aimed to elucidate the role of obesity in the pathogenesis of psoriasis, focusing on immunological changes. To induce obesity, mice were fed a high-fat diet for 20 weeks. We then applied imiquimod to the skin on a mouse's back for seven consecutive days to induce psoriasis and scored lesion severity every day for seven days. Cytokine levels in serum and the Th17 cell population in the spleen and draining lymph nodes were studied to identify immunological differences. The clinical severity was more remarkable, and histologically the epidermis was also significantly thicker in the obese group. Increased levels of IL-6 and TNF-α were observed in serum after psoriasis. They were elevated to a greater degree, with greater expansion of the functional Th17 cell population in the obese group. It is concluded that obesity could exacerbate psoriasis through mechanisms that involve elevated proinflammatory cytokine secretion and an expanded Th17 cell population.

Keywords: IL-6; Th17; imiquimod; obesity; psoriasis.

MeSH terms

  • Animals
  • Biomarkers
  • Cytokines / therapeutic use
  • Disease Models, Animal
  • Imiquimod / adverse effects
  • Interleukin-6* / adverse effects
  • Mice
  • Mice, Inbred C57BL
  • Obesity / etiology
  • Obesity / pathology
  • Psoriasis* / drug therapy
  • Skin / pathology
  • Th17 Cells

Substances

  • Imiquimod
  • Interleukin-6
  • Cytokines
  • Biomarkers

Grants and funding

This research received no external funding.